Gilead wins FDA nod for Trodelvy in new breast cancer indication

Feb. 03, 2023 10:56 AM ETGilead Sciences, Inc. (GILD)AZN, DSKYF, DSNKYBy: Dulan Lokuwithana, SA News Editor2 Comments

Maker Of Coronavirus Trial Drug Remdesivir, Gilead Sciences. Inc., Reports Positive Data Coming From Trials

Justin Sullivan/Getty Images News

Gilead Sciences (NASDAQ:GILD) announced Friday that the FDA approved its antibody-drug conjugate Trodelvy as a late-line option for certain adult patients with HR+/HER2- metastatic breast cancer.

While Trodelvy is already indicated in the U.S. for less

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.